AC Immune SA announces results of annual general meeting
November 15 2016 - 07:41AM
AC Immune Announces Results of Annual
General Meeting
AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical stage
biopharmaceutical company focused on neurodegenerative diseases,
today announced that the shareholders of the company have elected
Mr. Thomas Graney as a new member of the Board of Directors of the
Company at its Annual General Meeting held at EPFL Innovation Park,
Lausanne.
Martin Velasco, Chairman of the Board of Directors of AC
Immune, commented, "We are very pleased to welcome
Tom Graney to our Board of Directors, the Compensation, Nomination
and Corporate Governance Committee and the Finance and Audit
Committee. His experience in corporate finance and international
business and development will bring great expertise and experience
to our Board. This comes at the right time as we transition AC
Immune into a publicly traded company and continue to develop our
strong pipeline of therapeutics and diagnostics targeting
neurodegenerative disorders."
The shareholders of the company also approved all other
resolutions proposed. The detailed resolutions are available on
the company's website.Furthermore, AC Immune confirms that Dr.
Mathias Hothum has retired from the Board at the conclusion of the
Annual General Meeting.
About Mr. Tom Graney Mr. Graney serves as Chief
Financial Officer and Senior Vice President of Finance &
Corporate Strategy at Ironwood Pharmaceuticals, Inc., a post held
since September 2014. Prior to Ironwood his professional career
included 20 years with Johnson & Johnson and its affiliates,
serving for four years as Worldwide Vice President of Finance and
Chief Financial Officer of Ethicon, a Johnson & Johnson
company. In addition, Mr. Graney has extensive global experience
spanning corporate development, commercial strategy, portfolio
management and supply chain management. Mr. Graney is a Chartered
Financial Analyst charterholder and holds a B.S. in accounting from
the University of Delaware and an M.B.A. in marketing, finance and
international business from the Leonard N. Stern School of Business
at New York University.
About AC Immune AC Immune is a clinical stage
Swiss-based biopharmaceutical company focused on neurodegenerative
diseases with four product candidates in clinical trials. The
Company designs, discovers and develops therapeutic and diagnostic
products intended to prevent and modify diseases caused by
misfolding proteins. AC Immune's two proprietary technology
platforms create antibodies, small molecules and vaccines designed
to address a broad spectrum of neurodegenerative indications, such
as Alzheimer's disease. The Company's pipeline features seven
therapeutic and three diagnostic product candidates. The most
advanced of these is crenezumab, an anti-Abeta antibody in phase 3
clinical studies that is being advanced by the collaboration
partner Genentech, Inc., a wholly owned subsidiary of Roche. Other
business partners include Biogen, Janssen Pharmaceuticals, Nestlé
Institute of Health Sciences and Piramal Imaging.
Forward looking statements This press release
may contain statements that constitute "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Forward-looking
statements are statements other than historical fact and may
include statements that address future operating, financial or
business performance or AC Immune's strategies or expectations. In
some cases, you can identify these statements by forward-looking
words such as "may," "might," "will," "should," "expects," "plans,"
"anticipates," "believes," "estimates," "predicts," "projects,"
"potential," "outlook" or "continue," and other comparable
terminology. Forward-looking statements are based on management's
current expectations and beliefs and involve significant risks and
uncertainties that could cause actual results, developments and
business decisions to differ materially from those contemplated by
these statements. These risks and uncertainties include, but are
not limited to, the timing and conduct of clinical trials of AC
Immune's product candidates, the clinical utility of AC Immune's
product candidates, the timing or likelihood of regulatory filings
and approvals, AC Immune's intellectual property position and AC
Immune's financial position. These risks and uncertainties also
include those described under the captions "Risk Factors" and
"Management's Discussion and Analysis of Financial Condition and
Results of Operations" in AC Immune's Registration Statement on
Form F-1 and other filings with the Securities and Exchange
Commission. Forward-looking statements speak only as of the
date they are made, and AC Immune does not undertake any obligation
to update them in light of new information, future developments or
otherwise, except as may be required under applicable law. All
forward-looking statements are qualified in their entirety by this
cautionary statement.
For further information please contact:
Prof. Andrea Pfeifer Chief Executive Officer Phone: +41-21-345 91
21 E-mail:andrea.pfeifer@acimmune.com |
Eva Schier Corporate Communications Manager Phone: +41-21-345 91 34
Mobile: +41 79 926 66 03 E-mail: eva.schier@acimmune.com
|
Nick Miles/ Toomas Kull Cabinet Privé de Conseils s.a.
Phone : +41 22 321 45 40 E-mail : miles@cpc-pr.com
kull@cpc-pr.com |
In the US Ted Agne The Communications Strategy
Group Inc. Phone: +1 781 631 3117
E-mail: edagne@comstratgroup.com |
English: http://hugin.info/171580/R/2057046/770605.pdf
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From Feb 2024 to Mar 2024
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From Mar 2023 to Mar 2024